Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis.

Elenore Judy B UyKa Keat LimWarren FongHendra GohLinkai NgBenjamin HaalandJie Kie PhangLian Leng LowJoo Guan YeoFeng HuangYing Ying LeungJulian ThumbooTruls Østbye

Published in: Therapeutic advances in musculoskeletal disease (2020)

Our findings indicate no overall elevated risk of malignancy with biologics in SpA. As our meta-analyses are unable to conclude on the long-term risk, long-term pharmacovigilance of biologics in SpA may still be warranted.

Keyphrases

meta analyses
randomized controlled trial
ankylosing spondylitis
emergency department
disease activity
rheumatoid arthritis
electronic health record